Dermata Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Schedule of Equity Securities (Details) - shares	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares	260,000,000
Issued, shares	18,628,172
Abeyance, shares	4,232,470
Reserved, shares	63
Outstanding, shares	18,627,258
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares	250,000,000
Issued, shares	6,032,648
Abeyance, shares	4,232,470
Reserved, shares
Outstanding, shares	6,032,648	2,517,768	443,998	261,998
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares	10,000,000
Issued, shares
Abeyance, shares
Reserved, shares
Outstanding, shares
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares
Issued, shares	12,389,769
Abeyance, shares
Reserved, shares
Outstanding, shares	12,389,769
2021 Omnibus Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Authorized, shares
Issued, shares	205,755
Abeyance, shares
Reserved, shares	63
Outstanding, shares	204,841